Immutep Limited IMMP
Annual
Quarterly
No annual revenue total was found in Immutep Limited's SEC filings.
Immutep Limited (IMMP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
1.47B
+0.9% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMP (Nasdaq), PRRUF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Sydney,, Australia
- SEC filer status
- Accelerated filer
- SEC CIK
- 1506184
- Former names
- Prima BioMed Ltd (until Dec 1, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 28, 2026 |
| 20-F | Annual report (foreign issuer) | Oct 23, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Sep 22, 2026 | Sep 21, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
All 739 Immutep Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.